Allianz Asset Management GmbH cut its stake in Heska Corp (NASDAQ:HSKA) by 11.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,343 shares of the medical research company’s stock after selling 8,026 shares during the period. Allianz Asset Management GmbH owned 0.87% of Heska worth $5,081,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its stake in Heska by 96.9% in the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after purchasing an additional 499 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Heska in the 3rd quarter worth approximately $108,000. Municipal Employees Retirement System of Michigan boosted its stake in Heska by 58.9% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 2,400 shares of the medical research company’s stock worth $211,000 after purchasing an additional 890 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Heska by 46.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,438 shares of the medical research company’s stock worth $215,000 after purchasing an additional 776 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new stake in Heska in the 4th quarter worth approximately $206,000. Institutional investors own 85.92% of the company’s stock.
Shares of Heska Corp (NASDAQ HSKA) opened at $78.50 on Friday. Heska Corp has a 12 month low of $56.59 and a 12 month high of $115.00. The company has a market cap of $567.79, a P/E ratio of 59.92, a price-to-earnings-growth ratio of 2.15 and a beta of 0.82.
A number of analysts recently commented on the stock. BidaskClub upgraded shares of Heska from a “sell” rating to a “hold” rating in a research note on Friday. Canaccord Genuity restated a “buy” rating and set a $95.00 price objective on shares of Heska in a research note on Thursday, March 1st. TheStreet cut shares of Heska from a “b-” rating to a “c+” rating in a research note on Friday, March 9th. Raymond James Financial restated a “buy” rating on shares of Heska in a research note on Monday, December 4th. Finally, ValuEngine cut shares of Heska from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $104.08.
WARNING: This article was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://stocknewstimes.com/2018/03/17/heska-corp-hska-position-reduced-by-allianz-asset-management-gmbh.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.